Compare Amphastar Pharmaceuticals Inc (AMPH) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Gartner Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.54 (market cap $863.95M), while Gartner Inc trades at $187.34 (market cap $12.20B). The key difference: Gartner Inc is far larger — about 14.1× Amphastar Pharmaceuticals Inc's market cap, and Gartner Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | IT | |
|---|---|---|
Market Cap | $863.95M | $12.20B |
Sector | Health | Technology |
52-Week High | $30.81 | $264.09 |
52-Week Low | $16.87 | $125.68 |
Enterprise Value | $1.26B | $13.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Gartner (IT) trades at $185.6, up 0.42% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 69.63% gross margin and 12% net income margin, though revenue growth has moderated. Recent news highlights Q2 2026 earnings exceeding expectations and raised full-year EPS guidance, driving positive investor sentiment.
Outlook is supported by valuation discounts (P/E 16.69) and high ROE (113.58%), but risks include consulting segment weakness and negative net cash flow trends. Analysts are mixed with a $172.80 consensus target, suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
